{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+the+Test+product",
    "query": {
      "intervention": "Vehicle of the Test product"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 86,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+the+Test+product&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T20:07:17.173Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00483496",
      "title": "Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Solar Urticaria"
      ],
      "interventions": [
        {
          "name": "Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% alone (formula RV3131A-MV1211)",
          "type": "DRUG"
        },
        {
          "name": "bisoctrizole 10% alone (formula RV3131A-MV1237)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]",
          "type": "DRUG"
        },
        {
          "name": "V0096 CR vehicle (formula RV3131A-MV1197)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orfagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483496"
    },
    {
      "nct_id": "NCT05691244",
      "title": "Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Ischemic Stroke",
        "Cerebral Stroke"
      ],
      "interventions": [
        {
          "name": "Drug: Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "Sovateltide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmazz, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 514,
      "start_date": "2025-07-24",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05691244"
    },
    {
      "nct_id": "NCT02886702",
      "title": "A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tazarotene Cream 0.05%",
          "type": "DRUG"
        },
        {
          "name": "TAZORAC® (tazarotene) Cream 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fougera Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 855,
      "start_date": "2016-09-19",
      "completion_date": "2017-08-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02886702"
    },
    {
      "nct_id": "NCT06673654",
      "title": "A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib Topical Cream 1.5%",
          "type": "DRUG"
        },
        {
          "name": "OPZELURA (Ruxolitinib) Cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 476,
      "start_date": "2023-08-11",
      "completion_date": "2024-09-23",
      "has_results": false,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06673654"
    },
    {
      "nct_id": "NCT02611804",
      "title": "A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Diclofenac sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2015-10",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-05-05",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 30,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611804"
    },
    {
      "nct_id": "NCT07469228",
      "title": "A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tretinoin Gel Microsphere, 0.04%",
          "type": "DRUG"
        },
        {
          "name": "RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1043,
      "start_date": "2025-08-04",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07469228"
    },
    {
      "nct_id": "NCT01682811",
      "title": "Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neurofibromatoses"
      ],
      "interventions": [
        {
          "name": "Part 1 Levulan injection",
          "type": "DRUG"
        },
        {
          "name": "Part 1 Levulan surface application",
          "type": "DRUG"
        },
        {
          "name": "Part 1 Levulan surface application twice",
          "type": "DRUG"
        },
        {
          "name": "Part 1 Levulan surface application twice with microneedling",
          "type": "DRUG"
        },
        {
          "name": "Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1",
          "type": "DRUG"
        },
        {
          "name": "Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2",
          "type": "DRUG"
        },
        {
          "name": "Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harry T Whelan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-03-12",
      "completion_date": "2016-07-07",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682811"
    },
    {
      "nct_id": "NCT06742957",
      "title": "Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Type Psorisis"
      ],
      "interventions": [
        {
          "name": "Tapinarof Cream 1%",
          "type": "DRUG"
        },
        {
          "name": "VTAMA®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 560,
      "start_date": "2024-12-17",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06742957"
    },
    {
      "nct_id": "NCT06189638",
      "title": "Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Foot Ulcers"
      ],
      "interventions": [
        {
          "name": "Antimicrobial Peptide PL-5 Topical Spray and Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2024-01-30",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 3,
      "location_summary": "Vista, California • Miami, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06189638"
    },
    {
      "nct_id": "NCT07546214",
      "title": "A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tapinarof Cream, 1%",
          "type": "DRUG"
        },
        {
          "name": "Vtama® (Tapinarof) Cream, 1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 575,
      "start_date": "2025-10-13",
      "completion_date": "2026-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-25T20:07:17.173Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07546214"
    }
  ]
}